Shares of Eli Lilly and Company (NYSE:LLY) have received a consensus rating of “Hold” from the twenty-two brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $89.73.
A number of equities analysts have issued reports on the stock. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Wednesday, November 1st. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Berenberg Bank restated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Leerink Swann boosted their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th.
TRADEMARK VIOLATION NOTICE: “Eli Lilly and Company (LLY) Given Consensus Recommendation of “Hold” by Analysts” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/05/eli-lilly-and-company-lly-given-consensus-recommendation-of-hold-by-analysts.html.
Eli Lilly and (NYSE LLY) traded down $0.55 during trading on Friday, reaching $82.89. 4,092,443 shares of the company’s stock traded hands, compared to its average volume of 3,292,586. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market capitalization of $91,269.77, a P/E ratio of 20.27, a PEG ratio of 1.83 and a beta of 0.34. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the previous year, the firm posted $0.88 earnings per share. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. analysts predict that Eli Lilly and will post 4.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. Eli Lilly and’s dividend payout ratio is presently 98.58%.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 772,003 shares of company stock worth $64,837,441. Insiders own 0.20% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of LLY. Acrospire Investment Management LLC lifted its position in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC bought a new position in Eli Lilly and during the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA bought a new position in Eli Lilly and during the second quarter valued at approximately $129,000. Willingdon Wealth Management bought a new position in Eli Lilly and during the third quarter valued at approximately $138,000. Finally, Wealthcare Advisory Partners LLC bought a new position in Eli Lilly and during the third quarter valued at approximately $142,000. Hedge funds and other institutional investors own 76.61% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.